X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA NATCO PHARMA AJANTA PHARMA/
NATCO PHARMA
 
P/E (TTM) x 21.1 16.0 132.2% View Chart
P/BV x 5.0 17.2 28.8% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 AJANTA PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
NATCO PHARMA
Mar-14
AJANTA PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,818877 207.3%   
Low Rs1,106424 261.2%   
Sales per share (Unadj.) Rs239.5223.4 107.2%  
Earnings per share (Unadj.) Rs52.831.1 169.9%  
Cash flow per share (Unadj.) Rs59.540.3 147.8%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs230.0219.5 104.8%  
Shares outstanding (eoy) m88.7733.07 268.4%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x6.12.9 209.8%   
Avg P/E ratio x27.720.9 132.3%  
P/CF ratio (eoy) x24.616.1 152.2%  
Price / Book Value ratio x6.43.0 214.6%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m129,78221,504 603.5%   
No. of employees `0006.8NA-   
Total wages/salary Rs m3,7651,128 333.8%   
Avg. sales/employee Rs Th3,128.4NM-  
Avg. wages/employee Rs Th554.0NM-  
Avg. net profit/employee Rs Th689.7NM-  
INCOME DATA
Net Sales Rs m21,2587,389 287.7%  
Other income Rs m242167 144.6%   
Total revenues Rs m21,4997,556 284.5%   
Gross profit Rs m6,5841,793 367.1%  
Depreciation Rs m596304 195.8%   
Interest Rs m4366 1.1%   
Profit before tax Rs m6,2261,290 482.7%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,539309 498.6%   
Profit after tax Rs m4,6861,027 456.1%  
Gross profit margin %31.024.3 127.6%  
Effective tax rate %24.723.9 103.3%   
Net profit margin %22.013.9 158.5%  
BALANCE SHEET DATA
Current assets Rs m12,2363,681 332.4%   
Current liabilities Rs m3,4613,123 110.8%   
Net working cap to sales %41.37.6 546.1%  
Current ratio x3.51.2 299.9%  
Inventory Days Days6089 67.3%  
Debtors Days Days8459 144.0%  
Net fixed assets Rs m11,1407,685 145.0%   
Share capital Rs m177331 53.5%   
"Free" reserves Rs m20,2376,670 303.4%   
Net worth Rs m20,4147,259 281.2%   
Long term debt Rs m10955 1.1%   
Total assets Rs m24,48611,957 204.8%  
Interest coverage x1,519.44.5 33,599.6%   
Debt to equity ratio x00.1 0.4%  
Sales to assets ratio x0.90.6 140.5%   
Return on assets %19.211.7 164.4%  
Return on equity %23.014.2 162.2%  
Return on capital %30.520.7 147.2%  
Exports to sales %039.4 0.0%   
Imports to sales %05.7 0.0%   
Exports (fob) Rs mNA2,908 0.0%   
Imports (cif) Rs mNA421 0.0%   
Fx inflow Rs m11,6673,445 338.6%   
Fx outflow Rs m1,616703 229.9%   
Net fx Rs m10,0522,743 366.5%   
CASH FLOW
From Operations Rs m2,8541,440 198.2%  
From Investments Rs m-2,604-1,089 239.1%  
From Financial Activity Rs m-2-353 0.6%  
Net Cashflow Rs m248-1 -16,651.0%  

Share Holding

Indian Promoters % 73.8 52.0 141.8%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 1.6 7.8 19.8%  
FIIs % 7.6 16.6 45.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 26.0 65.4%  
Shareholders   20,968 25,395 82.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Up Over 240 Points; Rupee Touches Record Low(12:30 pm)

After opening the day in the green, stock markets in India have continued their momentum and are presently trading on a positive note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Should You Buy These Mouthwatering High Dividend Stocks?(Profit Hunter)

Aug 1, 2018

Many stocks are yielding dividends even upwards of 4%-5%. Here are the kinds you should pick, and the ones to avoid.

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

NFO - Axis Equity Hybrid Fund: A Worthy Proposition?(Outside View)

Aug 1, 2018

PersonalFN explains if NFO: Axis Equity Hybrid Fund, would be a worthy proposition currently.

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 14, 2018 01:45 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS